DEF 14A: Akari Therapeutics Seeks Shareholder Approval for Massive Equity Expansion and Director Compensation Amidst Widening Losses

Akari Therapeutics, Plc is seeking shareholder approval for a significant increase in its equity incentive plan, new share allotment authority, and director stock options, as the company reports a 32% decrease in cash and a near doubling of net losses for the fiscal year ended December 31, 2024.

Summary

• Akari Therapeutics, Plc (AKTX) is holding its 2025 Annual General Meeting (AGM) on June 30, 2025, in London, to vote on 16 resolutions.
• Key proposals include receiving the 2024 financial accounts, approving the Directors Remuneration Report, and re-electing six Class A directors.
• The company is seeking to increase the number of shares available under its 2023 Equity Incentive Plan by 11,026,000,000 ordinary shares (5,513,000 ADSs), bringing the total to 19,806,000,000 ordinary shares (9,903,000 ADSs), plus up to 855,637,300 ordinary shares from a prior plan.
• Shareholders will vote on approving time-vested one-time stock option awards granted to certain directors on March 20, 2025, totaling 1,350,000 ADSs (2,700,000,000 ordinary shares), representing 4.2% of the company's current issued share capital.
• The board is requesting authorization to allot shares up to an aggregate nominal amount of $20,000,000 (equivalent to 200,000,000,000 ordinary shares or 100,000,000 ADSs) until June 30, 2030.
• A special resolution seeks to disapply statutory pre-emption rights for cash allotments of equity securities, which would allow the company to raise funds more efficiently without offering them proportionally to existing shareholders first.
• The company reported a decrease in cash from $3,845,000 at December 31, 2023, to $2,599,000 at December 31, 2024, a 32% decline.
• Net income worsened from a loss of $10.0 million in 2023 to a loss of $19.8 million in 2024.
• Audit fees paid to BDO USA, P.C. increased from $344,384 in 2023 to $527,845 in 2024.
• The company's issued ordinary share capital as of June 4, 2025, was 64,352,739,523 ordinary shares, with each ADS representing 2,000 ordinary shares.
• The board of directors unanimously recommends voting FOR all proposed resolutions.
• The company has undergone significant management changes, including the appointment of Abizer Gaslightwala as President and CEO in April 2025, and Torsten Hombeck as CFO in December 2024, following the departure of previous executives.

Sentiment

Score: 3

Explanation: The sentiment is negative due to deteriorating financial performance (increased losses, decreased cash) and the significant potential for shareholder dilution from the proposed massive increase in authorized shares and the disapplication of pre-emption rights, which are necessary for the company's continued operation but adverse to existing shareholder value.

Positives

• The Board of Directors unanimously recommends voting in favor of all proposed resolutions, indicating internal alignment on strategic direction and governance matters.
• The proposed increase in the equity incentive plan and share allotment authority aims to provide the company with flexibility for future equity-based incentives and capital raises, which are crucial for a pre-revenue biotechnology company.
• The re-election of experienced directors, including those who joined following the Peak Bio, Inc. merger, suggests a stable and qualified leadership team.
• The adoption of a formal clawback policy in November 2023 aligns executive compensation with financial reporting integrity and shareholder interests.
• The separation of the Chairman and CEO roles is maintained, reinforcing board independence and oversight.

Negatives

• The company's cash balance decreased by 32% from $3,845,000 in 2023 to $2,599,000 in 2024, indicating a significant burn rate.
• Net income worsened, with losses increasing from $10.0 million in 2023 to $19.8 million in 2024, reflecting deteriorating financial performance.
• The proposed increase in shares available for equity awards and the authorization to allot up to 200,000,000,000 ordinary shares (100,000,000 ADSs) represents a substantial potential for future shareholder dilution.
• The request to disapply statutory pre-emption rights, while aimed at efficiency, removes existing shareholders' automatic right to participate proportionally in future cash equity raises, potentially leading to further dilution of their ownership percentage.
• Significant executive turnover occurred in 2024, with Rachelle Jacques stepping down as CEO and Wendy DiCicco as Interim CFO, which could indicate instability or strategic shifts.

Risks

• Failure to secure additional fundraisings may delay research and development activities, impacting the company's operating plan and pipeline advancement.
• The company's status as a pre-revenue-generating entity means it relies heavily on equity financings, exposing shareholders to significant dilution risk from future capital raises.
• Disapplication of statutory pre-emption rights could lead to existing shareholders being diluted without the opportunity to maintain their proportional ownership.
• The company acknowledges a potential 'competitive disadvantage' compared to U.S.-incorporated peers due to U.K. pre-emption rights, which the proposed resolution aims to mitigate.
• The conditional nature of the director stock option awards on shareholder approval of the share increase means that if the share increase is not approved, the company may need to take other compensatory actions to retain directors, potentially incurring different costs or challenges.

Future Outlook

Akari Therapeutics intends to seek additional fundraisings as necessary to implement its operating plan, with equity financings considered an appropriate method for future funding requirements. The company believes that having authorization to allot shares and disapply pre-emption rights will allow it to raise funds more efficiently and in a timely fashion, mitigating a competitive disadvantage compared to U.S.-incorporated peers. The strategic focus is on ADC (Antibody-Drug Conjugate) focused research and discovery activities following the business combination with Peak Bio Inc.

Management Comments

• "Your directors consider that each Resolution is in the best interests of the Company and its shareholders as a whole and is likely to promote the success of the Company."
• "Accordingly, your directors unanimously recommend that you vote in favor of the Resolutions as each of the directors with personal holdings of equity interests in the Company intends to do in respect of their own beneficial holdings."
• "We believe that the increase in the number of shares available for issuance under the 2023 Plan is essential to permit our management to continue to provide long-term, equity-based incentives to present and future key employees, consultants and directors."
• "Our executive compensation program is designed to reward value creation for shareholders and to attract, motivate, and retain our executive officers, who are critical to our success."
• "The Board believes that, in the event of an equity financing, having authorization to allot, or grant rights to subscribe for or convert securities into, our shares without needing to seek approval from shareholders at the time should allow Akari to raise funds more efficiently on the best terms available and in a timely fashion."
• "The Akari Board believes that it is appropriate to avoid Akari potentially being at a competitive disadvantage as compared to our peer companies listed on Nasdaq, many of whom are incorporated in the United States."

Industry Context

Akari Therapeutics operates in the biotechnology industry, characterized by high research and development costs and a reliance on external funding, especially for pre-revenue companies. The company's strategic reprioritization towards ADC-focused research and discovery activities aligns with a growing area of interest in oncology and targeted therapies. The discussion around pre-emption rights highlights a regulatory difference between U.K.-incorporated companies like Akari and their U.S.-incorporated Nasdaq-listed peers, where U.S. companies typically have more flexibility in issuing shares without pre-emptive offers, potentially giving them a fundraising advantage.

Comparison to Industry Standards

• The company notes that, unlike U.S.-incorporated companies listed on Nasdaq, U.K. companies are generally required to offer new shares to existing shareholders on a pre-emptive basis for cash allotments, which can add expense and delay to capital-raising activities. This places Akari at a competitive disadvantage compared to its U.S. peers who are not subject to such restrictions.
• The document does not provide specific financial or operational comparisons to named competitor companies or industry benchmarks beyond general statements about 'similar-sized biotechnology companies' and 'peer companies listed on Nasdaq'.

Management Changes

Corporate Governance

Related Party Transactions

• Samir Patel's Interim CEO Agreement: Dr. Patel received $50,000 per month, initially in fully vested ordinary shares, later changed to fully vested non-qualified stock options (NQSOs) with a value of two times the monthly cash amount in ADSs. In 2024, $0.3 million in non-cash stock-based compensation and 91,396,000 fully vested ordinary shares were recognized.
• Notes Payable Due to Dr. Hoyoung Huh: The company assumed two notes from Peak Bio acquisition (January 2024 Note for $0.75 million at 15% interest and 2021 Notes for $0.9 million at 1.0% interest). A portion of these notes ($1.0 million aggregate) was cancelled and extinguished in March 2025 for ordinary shares and warrants.
• May 2024 Convertible Notes: Issued to Dr. Raymond Prudo and Dr. Samir Patel for an aggregate of $1.0 million at 15% interest. $750,000 was repaid in cash in October 2024, and the remaining $250,000 (plus accrued interest) was converted into ADSs at $1.59 per ADS, with shares issued on April 30, 2025.
• The Doctors Laboratory (TDL): The company leases office space from TDL for approximately $0.1 million plus VAT annually and incurred approximately $0.1 million annually for laboratory testing and administrative services. Dr. Ray Prudo, a director, is the non-Executive Chairman of TDL.
• Amount due to an entity where Dr. Hoyoung Huh is a director: Less than $0.1 million was assumed in November 2024 and included in accounts payable as of December 31, 2024.

Stakeholder Impact

• **Shareholders**: Face significant potential dilution from the proposed increase in authorized shares and the disapplication of pre-emption rights, which could reduce their proportional ownership and value per share. However, these measures are presented as necessary for the company's continued operation and future funding.
• **Employees/Executives**: The proposed increase in the equity incentive plan and the approval of director stock options are intended to provide long-term, equity-based incentives, aiding in attraction, motivation, and retention of key personnel.
• **Creditors**: The company's declining cash balance and widening net losses may raise concerns about its ability to meet short-term obligations, although the proposed capital raises aim to address future funding needs.
• **Customers/Partners**: Continued funding through equity raises is crucial for the company's research and development activities, which directly impacts its ability to advance its pipeline and deliver future products or services.

Next Steps

• Shareholders to vote on 16 proposed resolutions at the Annual General Meeting on June 30, 2025.
• The company will continue to implement its operating plan, which is expected to require additional fundraisings.
• The Board and compensation committee will review and consider shareholder voting results on advisory resolutions (Remuneration Report, NEO compensation) when making future decisions.
• The directors' annual report on remuneration will be delivered to the U.K. Registrar of Companies following the AGM.
• The company will file a current report on Form 8-K with the SEC within four business days following the Meeting to announce voting results.

Key Dates

Recommendation

Keywords

Biotechnology, SEC Filing, Proxy Statement, Shareholder Meeting, Equity Incentive Plan, Share Allotment, Dilution, Corporate Governance, Executive Compensation, Risk Management, Capital Raise, Pre-emption Rights, Financial Performance, Board of Directors, Auditor Ratification, Biopharma